DUPLEX Sparsentan, It’s No Acthar Gel

The Filtrate get around to discussing DUPLEX, the randomized controlled trial that examined the use of the endothelin antagonist sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). While superficially this is a negative trial, in reality it is nephrology’s first attempt to study the treatment of FSGS using a contemporary, multicenter, active controlled protocol. While negative, nephrology and our patients with FSGS will gain valuable knowledge for treating patients with this condition.